litlas
Log inCreate account

Tadeusz Pieńkowski

Active 1997–2024

47
Papers
23,933
Citations
43
h-index
47
i10-index

Citations

Citations per year for Tadeusz Pieńkowski1974: 1 citations1998: 1 citations1999: 6 citations2000: 3 citations2001: 1 citations2002: 4 citations2003: 12 citations2004: 29 citations2005: 43 citations2006: 59 citations2007: 110 citations2008: 202 citations2009: 178 citations2010: 177 citations2011: 142 citations2012: 206 citations2013: 276 citations2014: 255 citations2015: 237 citations2016: 229 citations2017: 245 citations2018: 214 citations2019: 617 citations2020: 574 citations2021: 588 citations2022: 484 citations2023: 348 citations2024: 478 citations2025: 220 citations2026: 8 citations1975–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,021 citing papers, 23.7% of this breakdownChina: 573 citing papers, 6.7% of this breakdownItaly: 546 citing papers, 6.4% of this breakdownUnited Kingdom: 537 citing papers, 6.3% of this breakdownGermany: 446 citing papers, 5.2% of this breakdownSpain: 364 citing papers, 4.3% of this breakdownFrance: 344 citing papers, 4% of this breakdownCanada: 339 citing papers, 4% of this breakdownSwitzerland: 318 citing papers, 3.7% of this breakdownBelgium: 277 citing papers, 3.2% of this breakdownJapan: 224 citing papers, 2.6% of this breakdownAustralia: 212 citing papers, 2.5% of this breakdown
0%23.7%Other 27.4%

Institutions

Fields

  • Medicine67.2%
  • Biochemistry, Genetics and Molecular Biology27.1%
  • Immunology and Microbiology1.4%
  • Computer Science1.1%
  • Materials Science0.7%
  • Mathematics0.5%
  • Other2%

Topics

  • HER2/EGFR in Cancer Research14.4%
  • Breast Cancer Treatment Studies10.4%
  • Cancer Treatment and Pharmacology6%
  • Advanced Breast Cancer Therapies5.8%
  • Monoclonal and Polyclonal Antibodies Research4.7%
  • Chemotherapy-induced cardiotoxicity and mitigation2.5%
  • Other56.2%

Coauthors

All papers

Open in search
  1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Laslo Roman, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2011 cited by 2,358

  2. Adjuvant Trastuzumab in HER2-Positive Breast Cancer

    Authors: Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown - New England Journal of Medicine 2011 cited by 2,775

  3. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    Authors: José Baselga, Javier Cortés, Sung‐Bae Kim, Seock‐Ah Im, Roberto Hegg, Young‐Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pieńkowski, Adam Knott, Emma Clark, Mark Benyunes, Graham Ross, Sandra M. Swain - New England Journal of Medicine 2011 cited by 2,523

  4. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

    Authors: Christina Davies, Hongchao Pan, Jon Godwin, Richard Gray, R. Arriagada, Vinod Raina, Mirta Abraham, Victor Hugo Medeiros Alencar, A. S. Badran, Xavier Bonfill, Joan Bradbury, Michael Clarke, Rory Collins, Susan R. Davis, Antonella Delmestri, John Forbes, Peiman Haddad, Ming‐Feng Hou, Moshe Inbar, Hussein Khaled, Joanna Kielanowska, Wing-Hong Kwan, Beela Sarah Mathew, Indraneel Mittra, Bettina Müller, Antonio Nicolucci, O Peralta, Fany Pernas, Luboš Petruželka, Tadeusz Pieńkowski, Ramachandran Radhika, Balakrishnan Rajan, Maryna T Rubach, Sera Tort, Gerard Urrútia, Miriam Valentini, Yaochen Wang, Richárd Pető - The Lancet 2012 cited by 2,039

  5. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    Authors: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2016 cited by 874

  6. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Authors: Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron - New England Journal of Medicine 2006 cited by 3,461

  7. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

    Authors: Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jérusalem, Susan Dent, Linda Reaby, Hervé Bonnefoi, Ian E. Krop, Tsang‐Wu Liu, Tadeusz Pieńkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young‐Hyuck Im, Ling‐Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefanía Monturus, Mihaela Sicoe, Sébastien Guillaume, José Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen - Journal of Clinical Oncology 2021 cited by 359

  8. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Paul Ellis - Journal of Clinical Oncology 2017 cited by 413

  9. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

    Authors: Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe José Silva Melo Cruz, R. N. Safin, Sung‐Bae Kim, Christian Schem, Alberto J. Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M. Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Perez-Moreno, Joohyuk Sohn, for the acelERA Breast Cancer Study Investigators, G. Aguil, Marcos E. Alfie, Valeria Cáceres, Guillermo Lerzo, Sandra A. Ostoich, F. Boyle, Elgene Lim, Hayes Martin, Catherine Oakman, Felipe Melo Cruz, Fábio Franke, André Mattar, E.H. Silva, Katsuki Arima Tiscoski, Wei Chen, Wěi Li, Zhongsheng Tong, Jing Wang, Shaomeng Wang, X. Wang, Jiong Wu, Xiao‐Yuan Wu, Ju Yang, Q. Zhang, Till‐Oliver Emde, G. Gaffunder, Carsten Hielscher, Michael P. Lux, Christian Schem, Manfred Welslau, Claudia Schumacher, I. Kuchuk, T Peretz, Larisa Ryvo, R. Yerushalmi, Hee Dong Chae, Y.S. Chae, Seock‐Ah Im, Hwa Jung Kim, Jie‐Hyun Kim, S.-B. Kim, Jung Eun Lee, Y. H. Park, Joohyuk Sohn, Michał Jarząb, Monika Nowaczyk, Zbigniew Nowecki, Tadeusz Pieńkowski, Marek Z. Wojtukiewicz, Piotr J. Wysocki, E. Fomin, I. P. Ganshina, Nikolay Kislov, М. В. Копп, Н. В. Коваленко, Y. Makarova, Marina Matrosova, Р. В. Орлова, Artem Poltoratsky, Р. Р. Сафин, Р. А. Зуков, A. Wong, Yoon Sim Yap, M.A. Coccia-Portugal, Nicolaas H. Fourie, R. Khanyile, L. Schoeman, Ta‐Chung Chao, S.-T. Chen, Wei‐Pang Chung, Yin‐Hsun Feng, Yung‐Chang Lin, Thitiya Dejthevaporn, Napa Parinyanitikul, Chirawadee Sathitruangsak, Areewan Somwangprasert, Piyawan Tienchaianada, Ahmet Alacacıoğlu and 31 more - Journal of Clinical Oncology 2024 cited by 63

  10. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, Sanne de Haas, Silke Hoersch, Monika Patre, Paul Anthony Ellis - Cancer 2019 cited by 114

  11. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    Authors: David Cameron, Michelle Casey, Michael F. Press, Deborah Lindquist, Tadeusz Pieńkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiełło-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, B. Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen C. Rubin, Steven Stein, Charles E. Geyer - Breast Cancer Research and Treatment 2008 cited by 803

  12. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

    Authors: David Cameron, Julia Brown, Rebecca Dent, Christian Jackisch, John R. Mackey, Xavier Pivot, Guenther G. Steger, Thomas Suter, Masakazu Toi, Mahesh Parmar, R. Laeufle, Young‐Hyuck Im, Gilles Romieu, Vernon Harvey, Oleg Lipatov, Tadeusz Pieńkowski, Paul Cottu, Arlene Chan, Seock‐Ah Im, Peter S Hall, Lida Bubuteishvili‐Pacaud, Volkmar Henschel, Regula Deurloo, Céline Pallaud, Richard H. Bell - The Lancet Oncology 2013 cited by 436

  13. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

    Authors: Giampaolo Bianchini, Lajos Pusztai, Tadeusz Pieńkowski, Young‐Hyuck Im, Giulia Bianchi, Ling‐Ming Tseng, M.-C. Liu, Aňa Lluch, Eugenia Galeota, Domenico Magazzù, Juan de la Haba-Rodríguez, Do‐Youn Oh, Brigitte Poirier, José Luiz Pedrini, Semiglazov Vf, Pinuccia Valagussa, Luca Gianni - Annals of Oncology 2015 cited by 134

  14. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

    Authors: Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, Young‐Hyuck Im, Tadeusz Pieńkowski, Mei-Ching Liu, Ling‐Ming Tseng, Mitch Dowsett, Lila Zabaglo, S Kirk, Tania Szado, Jennifer Eng‐Wong, Lukas C. Amler, Pinuccia Valagussa, Luca Gianni - Breast Cancer Research 2017 cited by 129

  15. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

    Authors: Edith A. Perez, Sanne Lysbet de Haas, W. Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, S Stanzel, Monika Patre, Paul Anthony Ellis - BMC Cancer 2019 cited by 67

  16. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

    Authors: Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer, Dominik Heinzmann, Bert Lum, Sung‐Bae Kim, Tadeusz Pieńkowski, Mikhail Lichinitser, Semiglazov Vf, Bohuslav Melichar, Christian Jackisch - The Lancet Oncology 2012 cited by 346

  17. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

    Authors: Brian Leyland‐Jones, Semiglazov Vf, Marek Pawlicki, Tadeusz Pieńkowski, Sergei Tjulandin, George Manikhas, Antoly Makhson, Anton Roth, David Dodwell, José Baselga, M. Biakhov, Konstantinas Povilas Valuckas, Э К Возный, Xiangyang Liu, Els Vercammen - Journal of Clinical Oncology 2005 cited by 665

  18. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

    Authors: Vicente Valero, John Forbes, Mark D. Pegram, Tadeusz Pieńkowski, W. Eiermann, Gϋnter von Minckwitz, Henri Roché, Miguel Martín, John Crown, John R. Mackey, P. Fumoleau, Janusz Rolski, Zrinka Mršić-Krmpotić, Agnieszka Jagiełło-Gruszfeld, A. Riva, Marc Buyse, Henry Taupin, Guido Sauter, Michael F. Press, Dennis J. Slamon - Journal of Clinical Oncology 2010 cited by 259

  19. Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy

    Authors: Michael F. Press, Guido Sauter, Marc Buyse, Leslie Bernstein, Roberta Guzman, Angela Santiago, Ivonne Villalobos, W. Eiermann, Tadeusz Pieńkowski, Miguel Martín, Nicholas J. Robert, John Crown, Valerie Bée, Henry Taupin, Kerry Flom, Isabelle Tabah-Fisch, Giovanni M. Pauletti, Mark A. Lindsay, A. Riva, Dennis J. Slamon - Journal of Clinical Oncology 2010 cited by 220

  20. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

    Authors: Manuela Rabaglio, Zijie Sun, Karen N. Price, Monica Castiglione‐Gertsch, Hanne Hawle, Beat Thürlimann, Henning T. Mouridsen, Mario Campone, JF Forbes, Robert Paridaens, Marco Colleoni, Tadeusz Pieńkowski, Jean‐Marie Nogaret, István Láng, Ian Smith, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates - Annals of Oncology 2009 cited by 185

  21. Delays in diagnosis and treatment of breast cancer: a multinational analysis

    Authors: Jacek Jassem, Vahit Özmen, Florin Bacanu, Monika Drobnienė, J. Eglītis, K C Lakshmaiah, Zsuzsanna Kahán, Jozef Mardiak, Tadeusz Pieńkowski, Т. Yu. Semiglazova, Ljiljana Stamatović, Constanta Timcheva, S. Vasović, Damir Vrbanec, Piotr Zaborek - European Journal of Public Health 2013 cited by 148

  22. Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

    Authors: Sara A. Hurvitz, David J. Betting, Howard M. Stern, Emmanuel Quinaux, Jeremy Stinson, Somasekar Seshagiri, Ying Zhao, Marc Buyse, John R. Mackey, Adrian Driga, Sambasivarao Damaraju, Mark X. Sliwkowski, Nicholas J. Robert, Vicente Valero, John Crown, Carla I. Falkson, Adam Brufsky, Tadeusz Pieńkowski, W. Eiermann, Miguel Martín, Valerie Bée, Omkar Marathe, Dennis J. Slamon, John M. Timmerman - Clinical Cancer Research 2012 cited by 111

  23. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

    Authors: Sibylle Loibl, Jacek Jassem, Amir Sonnenblick, Damien Parlier, Eric P. Winer, Jonas Bergh, Richard D. Gelber, Eleonora Restuccia, Young‐Hyuck Im, Chiun‐Sheng Huang, Florence Dalenc, Isabel Calvo, Marion Procter, Carmela Caballero, Emma Clark, Alice Raimbault, Robin McConnell, Estefanía Monturus, Evandro de Azambuja, Henry L. Gómez, Judith M. Bliss, Giuseppe Viale, José Bines, Martine Piccart, Stefan Aebi, Michael Andersson, Jonas Bergh, José Bines, Judith M. Bliss, Hervé Bonnefoi, Carmela Caballero, David Cameron, Fátima Cardoso, Emma Clark, Evandro de Azambuja, Sanne de Haas, Susan Dent, Luis Fein, Elizabeth S. Frank, Richard D. Gelber, Michael Gnant, Henry Gómez, Seock‐Ah Im, Christian Jackisch, Wolfgang Janni, Jacek Jassem, Ian E. Krop, Sherko Kümmel, Tsang‐Wu Liu, Sherene Loi, Sibylle Loibl, Norikazu Masuda, Einav Nili Gam-Yal, Beatrice Nyawira, Tomás Pascual, Martine Piccart, Tadeusz Pieńkowski, Marion Procter, Eleonora Restuccia, Álvaro Rodríguez-Lescure, Thomas Suter, Christoph Thomssen, Vivianne C. G. Tjan‐Heijnen, Gianluca Tomasello, Manuel Roberto Torres Ulloa, Chris Twelves, Giuseppe Viale, Janice M. Walshe, Nicholas Wilcken, Eric P. Winer - Journal of Clinical Oncology 2024 cited by 30

  24. Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of 193mPt and 195mPt Radionuclides in Auger Electron Therapy

    Authors: Kamil Wawrowicz, Agnieszka Majkowska‐Pilip, Damian Gaweł, Ewelina Chajduk, Tadeusz Pieńkowski, Aleksander Bilewicz - Molecules 2021 cited by 30